BPC-157 vs Naltrexone
Extensively Studied vs FDA Approved
synergistic Mechanism-based · 50% BPC-157 reduces inflammation while Naltrexone promotes tissue repair. Reducing inflammation creates a more favorable environment for healing.
Molecular Data
BPC-157 Naltrexone
Weight 1,419.53 Da 341.40 Da
Half-life <30 minutes ~4 hours
Chain 15 amino acids —
Type Pentadecapeptide Opioid antagonist (C20H23NO4)
Key Benefits
BPC-157
01 Accelerated tendon, ligament, muscle, and bone healing
02 Localized tissue repair with direct targeting
03 Superior bioavailability
04 Anti-inflammatory effects
05 Angiogenesis promotion
06 Gastric and intestinal protection
Naltrexone
01 Broad anti-inflammatory and immunomodulatory effects via OGF-OGFr axis upregulation
02 Reduction in pro-inflammatory cytokines (TNF-alpha, IL-6, IL-12) through TLR4 antagonism
03 Compensatory upregulation of endogenous endorphins and enkephalins (200-300% increase)
04 Improved immune regulation and rebalancing of Th1/Th2/Th17 responses
05 Reduction in chronic pain through central and peripheral opioid system modulation
06 Potential improvement in mood, anhedonia, and overall well-being via endorphin enhancement
07 Extremely well-tolerated with minimal side effects at low doses
08 Low cost, especially as compounded LDN formulation
Dosing Protocols
BPC-157
250-500mcg / Once or twice daily
Tendon/Joint healing 250-500 mcg 1-2x daily
Serious injury 500-1000 mcg 2x daily
General healing 250-500 mcg 1-2x daily
Maintenance 250 mcg 1x daily
Naltrexone
1.5-4.5 mg/day (LDN) / Once daily at bedtime
Side Effects
BPC-157
Mild injection site redness
Injection site irritation
Possible mild digestive adjustment (oral)
Naltrexone
Vivid dreams or unusually intense dreaming - the most frequently reported side effect, typically diminishes over 1-2 weeks
Initial sleep disruption or insomnia during the first week of treatment
Mild nausea, particularly during the first few days
Transient headache during dose initiation or titration
Contraindications
Active cancer (due to angiogenic effects)
Pregnancy or breastfeeding
Blood thinners (consult doctor due to angiogenesis)
WADA prohibited for competitive athletes
Current use of opioid medications or active opioid dependence (must be opioid-free 7-10 days minimum)
Acute hepatitis or severe hepatic impairment (primarily relevant at full dose)
Known hypersensitivity to naltrexone
Anticipated need for opioid pain medication (e.g., upcoming surgery - discontinue LDN 3-7 days prior)
Research Evidence
BPC-157 Naltrexone
Status Extensively Studied FDA Approved
References 8 studies 5 studies
Latest July 2025 2023
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.